TScan Therapeutics, Inc.
TCRX· Nasdaq
TCRXTScan Therapeutics, Inc.
Filed Nov 9, 2022 · 10-Q · 40 days after period end · 0000950170-22-023507
| Metric | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|
| Revenue | $3.36M | $2.41M | $290.00K |
| Net Income | -$16.25M | -$15.84M | -$7.17M |
| EPS Diluted | -$0.67 | -$0.80 | -$7.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 9, 2022 · 40 d after period end
